top of page

A1's Top 5 Most Undervalued Nasdaq Stocks, By Our DDDD (Deep Dive Due Diligence) 

A1 Financial's 5 top undervalued Nasdaq stocks in a chart

5 Stocks with undeniable upside potential

March 31st, 2024

 Let's begin by saying that any investment is risky. When you invest, only do so on your own due diligence. Anything can happen:  When Covid news went worldwide in March 2020,

even the greats tumbled. Tesla fell to $103. Boeing fell to $113 pre-market, $145 avg EOD.

 Having said that, with Covid hopefully and largely a thing of the past, we wish to share our research and thoughts on the top 5 most undervalued stocks, after our deep dive of due diligence.

#1:XTIA XTI Aerospace Inc With today's news posted on MarketWatch, XTIA is now confirmed to have a float of 483K shares, with 1.93m overall. XTI 's evaluation was professionally set at $245 mill -$340 mill, +the $20m INPX eval, brings this

to an incredible max PT of $137-$191/share value. Currently under $2...I mean, I'm BUYING TODAY...HUGE....So is everyone in the company. 

#2: HOLO MicroCloud Hologram Inc Recently this stock did a mini HKD run, approx 1/3 of it in one day, reaching from $1.50 to $113. It is set to join a communications group, with their amazing holographic ChatGPT similation, and already offer

their services to an unknown EV maker in China, likely BYD.

With a micro float of 1.81m, its volume and volatility are legendary already. Any day, anything can happen. But even

long term holders can be rewarded, as the future of this

company is so bright, all their employees and investors should wear shades. PT=$32/sh

#3 LQR Liquor House Recently performing a 50% dividend

 in shares, and receiving many new orders, the future is

unlimited for this company. With a vibrant CEO, valued partnerships, and loyal investor base, this should quadruple

or more, soon. PT=$8/sh


#4  ATHA Athira Pharma, Inc. We needed a pharma stock for this list, and SBFM came in a close second to Athira. The financials are strong for a clinical pharma, with very little debt, the catalysts and insider chatter for its Alzheimer's treatments are extremely strong.


#5 VLCN Volcon, Inc

A small, but growing company, offering advanced ATVs, recently over $2, mysteriously dropped for no reason. Quite undervalued

for their massive production capabilities. PT=$3/sh 

Forward-Looking Statements
Certain statements in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Companies' current expectations and projections about future events that the Companies believe may affect its financial condition, results of operations, business strategy and financial needs. Shareholders can identify these forward-looking statements by words or phrases such as "may," "will," "expect," "anticipate," "aim," "estimate," "intend," "plan," "believe," "is/are likely to," "potential," "continue" or other similar expressions. The Companies undertake no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations that arise after the date hereof, except as may be required by law. These statements are subject to uncertainties and risks including, but not limited to, the uncertainties related to market conditions, and other factors discussed in the "Risk Factors" section of the registration statements on Form S-1 filed with the SEC and other filings with the SEC. Although the Companies believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Companies cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Companies; registration statements and other filings with the SEC. Additional factors are discussed in the Companies' filings with the SEC, which are available for review at

bottom of page